UK guidelines updated to allow supply of intranasal naloxone

UK guidelines have been updated to allow for the supply of intranasal naloxone by people who work in drug treatment services to people who are likely to witness an opioid-related overdose.

Naloxone is a medication that temporarily reverses the effects of an opioid overdose.

These guidelines previously only related to injectable naloxone – now all of the guidance that applies to intramuscular naloxone (Prenoxad) also applies to intranasal (Nyxoid).

SDF will be creating a resource in due course on intranasal naloxone – which was only recently licensed in Europe – however, the Scottish National Naloxone Programme is clear that there is no current national guidance suggesting that areas switch to supplying intranasal naloxone.

Intramuscular naloxone remains the preferred product but there may be certain groups that would prefer a needleless option.

If you would like to discuss the possible implementation of intranasal naloxone within your service, please get in touch with your local Naloxone Coordinator. If you are not sure who this is please get in touch with Kirsten Horsburgh, SDF’s Strategy Coordinator (Drug Death Prevention) at kirsten@sdf.org.uk

Click here to view the updated UK guidelines